Expression and Mutation Analysis of Her2 in Head and Neck Squamous Cell Carcinoma-Reference-Cited by-同舟云学术

Expression and Mutation Analysis of Her2 in Head and Neck Squamous Cell Carcinoma

Published:2009-12-16 Issue:5 Volume:28 Page:495-500
ISSN:0735-7907
Container-title:Cancer Investigation
language:en
Short-container-title:Cancer Investigation

Author:

Ali Mahmoud AL Sheikh,Gunduz Mehmet,Gunduz Esra,Tamamura Ryo,Beder Levent Bekir,Katase Naoki,Hatipoglu Omer Faruk,Fukushima Kunihiro,Yamanaka Noboru,Shimizu Kenji,Nagatsuka Hitoshi

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,General Medicine

Link

http://www.tandfonline.com/doi/pdf/10.3109/07357900903476778

Reference20 articles.

1. Global Cancer Statistics, 2002

2. The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors

3. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling

4. Expression and mutation analysis of epidermal growth factor receptor in head and neck squamous cell carcinoma

5. Mutational analysis of theHER2 gene in lung tumors from Caucasian patients: Mutations are mainly present in adenocarcinomas with bronchioloalveolar features

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent findings on the impact of ErbB receptors status on prognosis and therapy of head and neck squamous cell carcinoma;Frontiers in Medicine;2023-02-02

2. Nuclear HER3 expression improves the prognostic stratification of patients with HER1 positive advanced laryngeal squamous cell carcinoma;Journal of Translational Medicine;2021-09-27

3. Human epidermal growth factor receptor 2 expression in head and neck squamous cell carcinoma: Variation within and across primary tumor sites, and implications for antigen‐specific immunotherapy;Head & Neck;2021-03-04

4. Risk of Development of Second Primary Head and Neck Cancer following an Index Breast Cancer;Otolaryngology–Head and Neck Surgery;2017-10-17

5. Evolution of anti-HER2 therapies for cancer treatment;Cancer Treatment Reviews;2017-09